特一藥業(002728.SZ):藥品涵蓋了止咳、退熱、抗生素、抗病毒藥、消化系統等類別
格隆匯2月6日丨特一藥業(002728.SZ)在投資者互動平台表示,流感患者主要表現為發熱,常有咳嗽、咽喉痛、鼻塞、流涕等呼吸道症狀,伴有頭痛、肌肉痠痛等全身不適,有的會發生胃腸道的不適感。針對相關症狀來看,公司藥品涵蓋了止咳、退熱、抗生素、抗病毒藥、消化系統等類別。公司的核心產品止咳寶片具有百年曆史,在清代末期就享有盛譽,具有“宣肺祛痰、止咳平喘”之功效。此外,公司的產品用於止咳化痰方面的還有小兒止咳糖漿、小兒咳喘靈顆粒、羧甲司坦片;退燒方面的有布洛芬片、對乙酰氨基酚片、雙氯芬酸鈉腸溶片;治療咽喉痛的藥物有蒲地藍消炎片、咽炎片、複方魚腥草片、穿心蓮片;治療感冒(或打噴嚏、鼻塞)的藥物有感冒靈顆粒、複方氨酚烷胺膠囊;另外,公司的鋁碳酸鎂咀嚼片、楓蓼腸胃康片、蒙脱石散等用於治療胃腸道方面。目前上述藥品在正常生產、銷售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.